Check nearby libraries
Buy this book
Approved by the FDA in 2005 as the first drug with a race-specific indication on its label, BiDil was touted as a pathbreaking therapy to treat heart failure in black patients. Kahn reveals that, at the most basic level, BiDil became racial through legal maneuvering and commercial pressure as much as through medical understandings of how the drug worked. He examines the legal and calls for a more reasoned approach to using race in biomedical research and practice.
Check nearby libraries
Buy this book
Subjects
Public health, united states, Chemotherapy, Development, Pharmaceutical industry, Health and race, Hydralazine, Social aspects, United States, Pharmacogenetics, Medical care, African Americans, History, African americans, medical care, Political aspects, Therapeutic use, Heart Failure, Drug therapy, Ethnology, Isosorbide DinitrateShowing 2 featured editions. View all 2 editions?
Edition | Availability |
---|---|
1
Race in a Bottle: The Story of Bidil and Racialized Medicine in a Post-Genomic Age
2012, Columbia University Press
in English
0231531273 9780231531276
|
zzzz
Libraries near you:
WorldCat
|
2 |
aaaa
Libraries near you:
WorldCat
|
Book Details
Classifications
ID Numbers
Community Reviews (0)
Feedback?August 26, 2024 | Edited by MARC Bot | import existing book |
December 25, 2021 | Edited by ImportBot | import existing book |
October 18, 2020 | Edited by MARC Bot | import existing book |
August 3, 2020 | Edited by ImportBot | import existing book |
October 14, 2016 | Created by Mek | Added new book. |